Department of Hospital Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Thorac Cardiovasc Surg. 2011 May;141(5):1305-12. doi: 10.1016/j.jtcvs.2010.10.040. Epub 2011 Jan 17.
Our objectives were to evaluate short- and long-term mortality associated with new-onset atrial fibrillation after coronary artery bypass grafting and to identify preoperative and intraoperative patient characteristics associated with new-onset atrial fibrillation.
Three independent investigators comprehensively reviewed the literature using Medline from 1960, Web of Science from 1980, and Scopus from 1960. All searches were done through December 2009. Selected cohort studies were used to evaluate associations between new-onset atrial fibrillation after coronary artery bypass grafting or coronary bypass plus valve and short-term mortality (defined as 30-day or in-hospital mortality) and long-term mortality (defined as mortality ≥ 6 months). We excluded studies involving atrial flutter, off-pump coronary bypass, and isolated valve surgery. Heterogeneity among studies was accounted for by meta-analysis with random-effects models.
Eleven studies (n = 40,112) met our inclusion criteria. New-onset atrial fibrillation was associated with higher short-term mortality (3.6% vs 1.9%; odds ratio [OR], 2.29; 95% confidence interval [CI], 1.74-3.01; P < .00001; heterogeneity of effects, P = .002). Mortality risks at 1 year and 4 years were 2.56 (95% CI, 2.14-3.08) and 2.19 (95% CI, 1.97-2.45; P < .0001), respectively. Older age, lower ejection fraction, history of hypertension, heart failure, prior stroke, peripheral arterial disease, and longer cardiopulmonary bypass and aortic clamp times were associated with new-onset atrial fibrillation. Preoperative use of ß-blockers reduced occurrence of new-onset atrial fibrillation (OR, 0.94 [95% CI, 0.88-1.01; P = .08]), whereas angiotensin-converting enzyme inhibitors increased it (OR, 1.20 [95% CI, 1.11-1.29], P < .00001).
New-onset atrial fibrillation after coronary artery bypass grafting appears to increase short- and long-term mortality. Preoperative use of ß-blockers, avoidance of angiotensin-converting enzyme inhibitors, and shorter cardiopulmonary bypass and aortic clamp times potentially reduce occurrence of new-onset atrial fibrillation.
评估冠状动脉旁路移植术后新发心房颤动与短期和长期死亡率之间的关系,并确定与新发心房颤动相关的术前和术中患者特征。
三位独立的研究者使用 Medline(从 1960 年开始)、Web of Science(从 1980 年开始)和 Scopus(从 1960 年开始)进行了全面的文献检索,所有检索均截止至 2009 年 12 月。选择队列研究来评估冠状动脉旁路移植术后或冠状动脉旁路加瓣膜后的新发心房颤动与短期死亡率(定义为 30 天或院内死亡率)和长期死亡率(定义为死亡率≥6 个月)之间的关系。我们排除了涉及心房扑动、非体外循环冠状动脉旁路移植术和单纯瓣膜手术的研究。通过使用随机效应模型的荟萃分析来解释研究之间的异质性。
11 项研究(n=40112)符合我们的纳入标准。新发心房颤动与短期死亡率增加相关(3.6%比 1.9%;比值比[OR],2.29;95%置信区间[CI],1.74-3.01;P<0.00001;效应异质性,P=0.002)。1 年和 4 年的死亡率风险分别为 2.56(95%CI,2.14-3.08)和 2.19(95%CI,1.97-2.45;P<0.0001)。年龄较大、射血分数较低、高血压史、心力衰竭、既往卒中、外周动脉疾病以及心肺转流和主动脉夹闭时间较长与新发心房颤动相关。术前使用β受体阻滞剂可降低新发心房颤动的发生率(OR,0.94[95%CI,0.88-1.01;P=0.08]),而血管紧张素转换酶抑制剂则会增加其发生率(OR,1.20[95%CI,1.11-1.29],P<0.00001)。
冠状动脉旁路移植术后新发心房颤动似乎会增加短期和长期死亡率。术前使用β受体阻滞剂、避免使用血管紧张素转换酶抑制剂以及缩短心肺转流和主动脉夹闭时间可能会降低新发心房颤动的发生率。